Driving prohibition Cognitive/motor impairment akin to alcohol intoxication
In vivo preclinical models investigating musculoskeletal injury, dermal repair, gastrointestinal integrity, or inflammatory conditions through pathways involving angiogenesis, ECM turnover, and cellular protection
Side-by-Side Comparison Parameter Receptors Cagrilintide AMY1R/2R/3R + CTR Semaglutide GLP-1R Tirzepatide GLP-1R + GIPR Retatrutide GLP-1R + GIPR + Glucagon-R Parameter Half-life Cagrilintide ~7-8 days Semaglutide ~7 days Tirzepatide ~5 days Retatrutide ~6 days Parameter Dosing frequency Cagrilintide Once weekly Semaglutide Once weekly Tirzepatide Once weekly Retatrutide Once weekly Parameter Max studied dose Cagrilintide 4.5 mg/week (mono) Semaglutide 2.4 mg/week Tirzepatide 15 mg/week Retatrutide 12 mg/week Parameter Peak monotherapy weight loss Cagrilintide 11.8% at 68 wk Semaglutide 14.9-17% at 68 wk Tirzepatide 22.5% at 72 wk Retatrutide ~24% at 48 wk Parameter FDA status (June 2026) Cagrilintide Investigational Semaglutide Approved (2021) Tirzepatide Approved (2023) Retatrutide Investigational Parameter HbA1c reduction (T2D) Cagrilintide ~0.9 pp mono
Drugging p53 in cancer: one protein, many targets
Your Direct Health membership also includes wellness visits, lab testing, X-ray, Mammography, Bone Density Testing, IV Therapy, Allergy Testing, EKG, and in-house prescription dispensing
Having treated thousands of patients with various types of foot pain, including plantar fasciitis, I can tell you that its rarely just a foot issue
